drugset / Trial / NCT03509831
[KJ-INT-002] BE Study
RandomizedCrossoverOpen-labelTreatment
Summary
Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects
Timeline
- Start
- 2017-11-02
- Primary completion
- 2018-01-24
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INT-2150 | Unknown | — | Oral |
| Subject | Irsogladine | Small molecule | 2 mg | — |
| Subject | Nizatidine | Small molecule | 150 mg | — |